Recent Articles in Top Stories

Quan Capital, a Shanghai healthcare venture firm, closed its second fund with $275 million in commitments, according to media reports. In 2018, Quan announced it would begin fundraising for second fund with a $300 million target, one year after it closed its $150 million initial fund. Quan is very closely allied with Zai Lab. Samantha Du, PhD, heads both companies and other members of Zai's senior management are also part of Quan's team. Quan seeks venture and growth investments in disruptive companies globally and in China. More details....

Stock Symbol: (NSDQ: ZLAB)

Share this with colleagues:

HiFiBiO Therapeutics, a Boston, France and Hangzhou company that develops therapeutic immune modulators, closed a $67 Million Series C financing round led by new investor IDG Capital. The company discovers novel drug candidates for cancer and autoimmune disorders using its proprietary single-B-cell screening and analysis platform. In May 2018, HiFiBiO completed a $38 million B round, which like the present financing, included predominantly China investors. More details....

Share this with colleagues:

Biotheus, a China biopharma based in Zhuhai, Guangdong, announced a $142 million agreement to in-license greater China rights for a TNFR antibody developed by Alligator Bio of Stockholm. Formed in 2018, Biotheus will have rights for up to three bi-specific candidates based on the antibody. The agreement, which specifies a $1 million upfront payment, will include a $90 million option for Biotheus to acquire global rights to the candidates. Biotheus is developing a pipeline of me-better/novel candidates focused on immuno-oncology and metabolic disease. More details....

Stock Symbol: (NSDQ Stockholm: ATORX)

Share this with colleagues:

Nanjing Frontier Biotechnologies was approved to stage a $285 million IPO on the Shanghai STAR Exchange. Frontier has a China approved treatment for HIV, and it is developing another HIV treatment that it in-licensed from the Rockefeller University of New York City. Founded in 2002 by returnees, Frontier has developed a long-acting peptide drug discovery-development platform that is designed to transform any peptide drug into a long-acting agent. Frontier is developing its own drugs, but it also offers its platform to outside companies to develop long-acting formulations. More details....

Share this with colleagues:

China's Chipscreen Bio gained a stunning 367% in its first trading session following its IPO on the Shanghai STAR exchange, giving the company a market cap of $4.2 billion, When the first 25 STAR Board IPOs hit the market last month, the average gain was 140%, which was considered a huge jump. Chipscreen was 2.5 times larger. Chipscreen develops small molecule drugs for cancer, diabetes, endocrine and autoimmune diseases. It priced its IPO 27% above its original target and raised $148 million, an amount that now seems charmingly quaint. More details....

Stock Symbol: (SHA: 688321)

Share this with colleagues: